Janka Carman1, Primož Strojan1. 1. Department of Radiation Oncology, Institute of Oncology Ljubljana, Zaloška 2, SI-1000 Ljubljana, Slovenia.
Abstract
AIM: To review the treatment results and identify prognostic factors for disease control and survival in a cohort of nasopharyngeal carcinoma (NPC) patients from a non-endemic population in Slovenia, diagnosed between 1990 and 2003. BACKGROUND: In Caucasians, nasopharyngeal carcinoma is a rare malignant tumor. Its diagnosis and treatment are complex and have been dramatically impacted by recent technological advances. MATERIALS AND METHODS: In the Cancer Registry of Slovenia database, a total of 126 patients with NPC were identified, 93 of whom were available for analysis. All patients were treated with conventional two-dimensional radiotherapy (RT) and 29.3% underwent chemotherapy (ChT). RESULTS: The median follow-up time for those alive at the last follow-up examination was 74.5 months. Disease recurred locally in 17 patients, regionally in 4 patients and at distant sites in 18 patients, resulting in 5-year locoregional control (LRC), distant failure-free survival (DFFS) and disease-free survival (DFS) of 73.7%, 78.6% and 59.3%, respectively. Disease-specific survival at 5 years was 59% and overall survival (OS) was 49.7%. In a multivariate analysis, LRC was favorably affected (P < 0.05) by an undifferentiated histology (hazard ratio [HR] = 2.86), DFFS through the absence of neck metastases (HR = 0.28), DFS by younger age (HR = 0.46), and more intensive RT (expressed as the isoeffective dose, EQD2,T ; HR = 2.08). The independent prognosticator for OS was age (≤55 years vs. >55 years, HR = 0.39); in the ≤55 years subgroup, an improved OS was connected to a more intensive RT regimen of EQD2,T ≥ 66 Gy (HR = 4.17). CONCLUSIONS: Our results confirm an independent and favorable effect from an undifferentiated histology, the absence of neck metastases, a younger patient age at diagnosis, and more intensive RT regimens for disease control and survival.
AIM: To review the treatment results and identify prognostic factors for disease control and survival in a cohort of nasopharyngeal carcinoma (NPC) patients from a non-endemic population in Slovenia, diagnosed between 1990 and 2003. BACKGROUND: In Caucasians, nasopharyngeal carcinoma is a rare malignant tumor. Its diagnosis and treatment are complex and have been dramatically impacted by recent technological advances. MATERIALS AND METHODS: In the Cancer Registry of Slovenia database, a total of 126 patients with NPC were identified, 93 of whom were available for analysis. All patients were treated with conventional two-dimensional radiotherapy (RT) and 29.3% underwent chemotherapy (ChT). RESULTS: The median follow-up time for those alive at the last follow-up examination was 74.5 months. Disease recurred locally in 17 patients, regionally in 4 patients and at distant sites in 18 patients, resulting in 5-year locoregional control (LRC), distant failure-free survival (DFFS) and disease-free survival (DFS) of 73.7%, 78.6% and 59.3%, respectively. Disease-specific survival at 5 years was 59% and overall survival (OS) was 49.7%. In a multivariate analysis, LRC was favorably affected (P < 0.05) by an undifferentiated histology (hazard ratio [HR] = 2.86), DFFS through the absence of neck metastases (HR = 0.28), DFS by younger age (HR = 0.46), and more intensive RT (expressed as the isoeffective dose, EQD2,T ; HR = 2.08). The independent prognosticator for OS was age (≤55 years vs. >55 years, HR = 0.39); in the ≤55 years subgroup, an improved OS was connected to a more intensive RT regimen of EQD2,T ≥ 66 Gy (HR = 4.17). CONCLUSIONS: Our results confirm an independent and favorable effect from an undifferentiated histology, the absence of neck metastases, a younger patient age at diagnosis, and more intensive RT regimens for disease control and survival.
Authors: Dominic A X Schinagl; Henri A M Marres; Arnoud C Kappelle; Matthias A W Merkx; Lucas A M Pop; Suzan M M Verstappen; Johannes H A M Kaanders Journal: Int J Radiat Oncol Biol Phys Date: 2010-03-16 Impact factor: 7.038
Authors: D M Heng; J Wee; K W Fong; L G Lian; V K Sethi; E T Chua; T L Yang; H S Khoo Tan; K S Lee; K M Lee; T Tan; E J Chua Journal: Cancer Date: 1999-11-15 Impact factor: 6.860
Authors: G Sanguineti; F B Geara; A S Garden; S L Tucker; K K Ang; W H Morrison; L J Peters Journal: Int J Radiat Oncol Biol Phys Date: 1997-03-15 Impact factor: 7.038
Authors: Anne W M Lee; W M Sze; Joseph S K Au; S F Leung; T W Leung; Daniel T T Chua; Benny C Y Zee; Stephen C K Law; Peter M L Teo; Stewart Y Tung; Dora L W Kwong; W H Lau Journal: Int J Radiat Oncol Biol Phys Date: 2005-03-15 Impact factor: 7.038
Authors: Wendy Hara; Billy W Loo; Don R Goffinet; Steven D Chang; John R Adler; Harlan A Pinto; Willard E Fee; Michael J Kaplan; Nancy J Fischbein; Quynh-Thu Le Journal: Int J Radiat Oncol Biol Phys Date: 2007-12-31 Impact factor: 7.038
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Susanna Hilda Hutajulu; Daniel Howdon; Kartika Widayati Taroeno-Hariadi; Mardiah Suci Hardianti; Ibnu Purwanto; Sagung Rai Indrasari; Camelia Herdini; Bambang Hariwiyanto; Ahmad Ghozali; Henry Kusumo; Wigati Dhamiyati; Sri Retna Dwidanarti; I Bing Tan; Johan Kurnianda; Matthew John Allsop Journal: PLoS One Date: 2021-02-12 Impact factor: 3.240
Authors: Amel El Korbi; Sarra Ben Tkhayat; Rachida Bouatay; Mehdi Ferjaoui; Naourez Kolsi; Khaled Harrathi; Jamel Koubaa Journal: Pan Afr Med J Date: 2021-02-09